Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presents with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis for at least 6 months prior to randomization~* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization~* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization~* Candidate for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Pustular, erythrodermic, and/or guttate forms of psoriasis~* History of drug-induced psoriasis~* Prior use of etanercept~* Clinically significant flare of psoriasis during the 12 weeks prior to randomization~* Concurrent or recent use of any biologic agent~* Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens and ultraviolet A \[PUVA\], ultraviolet B \[UVB\]) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than plaque psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
- 50 mg etanercept (Type: ACTIVE_COMPARATOR): Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
- 80 mg ixekizumab Dosing Regimen 2 (Type: EXPERIMENTAL): Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
- 80 mg ixekizumab Dosing Regimen 1 (Type: EXPERIMENTAL): Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).